Dyne Therapeutics, Inc.
Undisclosed program
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on Undisclosed program for its lead indication is in focus around Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“Dyne has aligned with the FDA on the Phase 3 trial design and protocol, which was presented at the 2026 MDA Clinical & Scientific Conference.”